← Back to all signals
RESEARCH PAPER ANALYSIS

The evolution of trends and technology in wearable sensors used to detect falls in people with neurodegenerative diseases: a systematic review.

Systematic review of 89 studies (predominantly in Parkinson's disease) characterizing wearable sensor types, placements (ankle common), and machine-learning algorithms for fall detection and calling for standardized, real-world validation.

PMID41907649
JournalFrontiers in neurorobotics
Publication Date2026-01-01
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

Systematic review of 89 studies (predominantly in Parkinson's disease) characterizing wearable sensor types, placements (ankle common), and machine-learning algorithms for fall detection and calling for standardized, real-world validation.

WHY IT MATTERS

Research significance

Although it doesn't address molecular or therapeutic mechanisms, the paper is useful for Parkinson's drug development because robust, validated wearable fall-detection tools can supply objective real-world endpoints, safety monitoring, and patient stratification to improve clinical trials and care.

ABSTRACT

Source abstract

BACKGROUND: Neurodegenerative diseases (NDs) are a significant threat to human health. Numerous research demonstrated that patients with NDs might present with decreased balance, which is responsible for an increased risk of falling. As an emerging technology, wearable devices can detect falls and prevent privacy breaches. OBJECTIVE: To access the evolution of trends and technology in wearable devices to detect falls among patients with NDs. METHODS: We screened PubMed and Web of Science (February 2023) to summarize the pathway of fall detection with any body-worn sensor. Included articles were required to be full-text and published in English. Documents were excluded if they; (1) only used wearable devices for fall cueing, (2) did not offer sufficient information for data extraction, (3) did not use patients with NDs, (4) only used non-wearable sensors or devices. RESULTS: The review identified 89 articles at the end of the procedure for data extraction. A wide variety existed in participant sample size (1-131), sensor types, placement and algorithms. 97.75% of papers (n = 87) used patients with Parkinson's disease as experimental subjects. 21.45% of studies attached devices on the ankle (n = 19), with a clear preference for using multiple types of sensors (58.43% of studies, n = 52). As the most commonly used inertial measurement unit (IMU), 21 articles utilized accelerometers and gyroscopes to assess falls. 39.33% of studies (n = 35) choose data set to verify the effectiveness of their algorithm. Machine learning algorithms have become prevalent since 2019, and the most commonly used algorithm was support vector machine (SVM) (n = 17). CONCLUSION: These results show that an increasing number of researchers examine the validation performance of their systems in non-real-time. The ankle was the preferred location among researchers, and there is a clear preference to use multiple types of sensors and machine learning algorithms to improve accuracy and immediacy. Future work should focus on other NDs instead of limiting to Parkinson's disease and consider an adequately studied population. A consensus on walking tasks and accuracy measurements is urgently needed. Performing studies in a simulated free-living environment for a specified time frame is advisable, with continuous real-time monitoring and assessment. SYSTEMATIC REVIEW REGISTRATION: PROSPERO, identifier (CRD42023405952).

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic